TY - JOUR
T1 - Issues related to development of new antiseizure treatments
AU - Wilcox, Karen S.
AU - Dixon-Salazar, Tracy
AU - Sills, Graeme J.
AU - Ben-Menachem, Elinor
AU - White, H. Steve
AU - Porter, Roger J.
AU - Dichter, Marc A.
AU - Moshé, Solomon L.
AU - Noebels, Jeffrey L.
AU - Privitera, Michael D.
AU - Rogawski, Michael A.
PY - 2013/8
Y1 - 2013/8
N2 - This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.
AB - This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.
KW - Animal models of epilepsy
KW - Antiseizure drug
KW - Pharmacoresistant epilepsy
UR - http://www.scopus.com/inward/record.url?scp=84891676185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891676185&partnerID=8YFLogxK
U2 - 10.1111/epi.12296
DO - 10.1111/epi.12296
M3 - Article
C2 - 23909851
AN - SCOPUS:84891676185
SN - 0013-9580
VL - 54
SP - 24
EP - 34
JO - Epilepsia
JF - Epilepsia
IS - SUPPL.4
ER -